Discover open access scientific publications

Search, annotate, share and cite publications

Publications in Oncology

P3.15-27 Initial Response to First Line Treatment Is the Best Predictor of the Patient Survival in Advanced NSCLC

Journal of Thoracic Oncology

English

YI 01.11 the Young Investigator Travel Award Experience - A Report From a Previous Award Winners

Journal of Thoracic Oncology

English

P1.16-55 Surgical Treatment for Lung Cancer. Subaortic (Para-Aortic) Lymph Nodes Involvement - N1 or N2 Disease?

Journal of Thoracic Oncology

English

S01.04 Lung Cancer Screening: 1999 to Date – What Have We Learnt?

Journal of Thoracic Oncology

English

P1.01-34 Docetaxel Plus Ramucirumab With Prophylactic PEG-G-CSF Support for Chemo-NaïVe Elderly NSCLC Patients: A Phase II Study (WJOG9416L)

Journal of Thoracic Oncology

English

MA02.08 the Effect of Nabilone on Appetite, Nutritional Status, and Quality of Life in Lung Cancer Patients: A Randomized, Double-Blind Clinical Trial

Journal of Thoracic Oncology

English

MA01.03 an Externally Validated Nomogram for Predicting Distant Metastasis After SBRT for Early Stage Non-Small Cell Lung Cancer

Journal of Thoracic Oncology

English

MA12.07 gC1qR Expression Is Independently Prognostic for Survival Benefit Following Chemotherapy in Mesothelioma

Journal of Thoracic Oncology

English

OA01.07 Updated Results of a Phase II Trial of Concurrent Chemoradiation With Consolidation Pembrolizumab in Patients With Unresectable Stage III NSCLC

Journal of Thoracic Oncology

English

The Significance of Low PU.1 Expression in Patients With Acute Promyelocytic Leukemia

Journal of Hematology and Oncology

English

Amanote Research

Discover open access scientific publications

Search, annotate, share and cite publications

Publications in Oncology

P3.15-27 Initial Response to First Line Treatment Is the Best Predictor of the Patient Survival in Advanced NSCLC

YI 01.11 the Young Investigator Travel Award Experience - A Report From a Previous Award Winners

P1.16-55 Surgical Treatment for Lung Cancer. Subaortic (Para-Aortic) Lymph Nodes Involvement - N1 or N2 Disease?

S01.04 Lung Cancer Screening: 1999 to Date – What Have We Learnt?

P1.01-34 Docetaxel Plus Ramucirumab With Prophylactic PEG-G-CSF Support for Chemo-NaïVe Elderly NSCLC Patients: A Phase II Study (WJOG9416L)

MA02.08 the Effect of Nabilone on Appetite, Nutritional Status, and Quality of Life in Lung Cancer Patients: A Randomized, Double-Blind Clinical Trial

MA01.03 an Externally Validated Nomogram for Predicting Distant Metastasis After SBRT for Early Stage Non-Small Cell Lung Cancer

MA12.07 gC1qR Expression Is Independently Prognostic for Survival Benefit Following Chemotherapy in Mesothelioma

OA01.07 Updated Results of a Phase II Trial of Concurrent Chemoradiation With Consolidation Pembrolizumab in Patients With Unresectable Stage III NSCLC

The Significance of Low PU.1 Expression in Patients With Acute Promyelocytic Leukemia